Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xbrane To File Ranibizumab Biosimilar In Europe And US Within 12 Months

Company Confirms Trials On Track For Approval Before Lucentis EU Patent Expiry

Executive Summary

Sweden’s Xbrane is aiming to file for approval of its Xlucane (ranibizumab) biosimilar to Lucentis in Europe and the US, and license the rights for the product’s sale and marketing of in Latin America, Japan and China, in the next 12 months.

You may also be interested in...

Samsung Bioepis First To File EU Lucentis Rival

Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.

Stada Raises Sales And Earnings But Admits ‘Tough’ Q2

Privately-owned Stada provided little insight into the exact mechanics of its operations for the first six months of 2020 but nevertheless said it had enjoyed an “above-market sales and earnings increase.” However, a raft of one-off expenses bit into the German firm’s profitability.

Xbrane Expands Capacity To Target More Biosimilars

Sweden’s Xbrane Biopharma is moving to new premises that will expand its development capacity and allow it to target several blockbuster biologics with patents expiring over the next decade.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts